TopFunds

Regeneron Pharmaceuticals

NASDAQ: REGN

Stock price

739.57 USD

(+0%) TODAY

Biotechnology
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
5.5
7.7
10.3
21.3
18.5
30.5
72
38.2
34.8
38.3
41.5
22.4%
02Free cash flow per share
5.7
8.4
8.9
15.8
17.5
17.4
58.2
39
32.3
31.8
37.6
20.8%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
3.5
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
8.2%
-
PROFIT AND LOSS STATEMENT
05Revenue
4,104
4,860
5,872
6,711
6,558
8,497
16,072
12,173
13,117
14,202
14,343
13.3%
06% Change
-
-
-
-
-
-
-
-
-
-
-
13.3%
07Cost of revenue
(467.6)
(404.4)
(542.5)
(582.3)
(975.4)
(1,356)
(2,724)
(1,705)
(2,245)
(1,971)
(2,101)
16.2%
08Gross profit
3,636
4,456
5,330
6,129
5,582
7,141
13,348
10,468
10,873
12,232
12,242
12.9%
09% Margin
88.6%
91.7%
90.8%
91.3%
85.1%
84%
83.1%
86%
82.9%
86.1%
85.4%
86.8% A
10Operating expenses
(2,384)
(3,125)
(3,250)
(3,594)
(3,372)
(3,565)
(4,401)
(5,082)
(6,524)
(8,241)
(8,664)
13.8%
11% of Revenue
(58.1)%
(64.3)%
(55.4)%
(53.6)%
(51.4)%
(42)%
(27.4)%
(41.8)%
(49.7)%
(58)%
(60.4)%
(51.1)% A
12Operating Income
1,252
1,331
2,080
2,534
2,210
3,577
8,947
5,386
4,349
3,991
3,578
11.1%
13Income tax expense
(589)
(434.3)
(880)
(109.1)
(313.3)
(297.2)
(1,251)
(520.4)
(245.7)
(367.3)
(725.8)
2.1%
14Net Income
636.1
895.5
1,199
2,444
2,116
3,513
8,075
4,338
3,954
4,413
4,505
21.6%
15% Margin
15.5%
18.4%
20.4%
36.4%
32.3%
41.4%
50.3%
35.6%
30.1%
31.1%
31.4%
31.2% A
16Shares Outstanding
115.2
116.3
115.9
114.8
114.6
115.1
112.2
113.5
113.7
115.1
108.6
(0.6)%
17EPS Basic
6.2
8.6
11.3
21.3
19.4
32.7
76.4
40.5
37.1
40.9
43.1
21.5%
18EPS Diluted
5.5
7.7
10.3
21.3
18.5
30.5
72
38.2
34.8
38.3
41.5
22.4%
19EBITDA
1,314
1,442
2,249
2,730
2,670
4,103
9,669
5,260
4,693
5,318
5,818
16%
% Margin
32%
29.7%
38.3%
40.7%
40.7%
48.3%
60.2%
43.2%
35.8%
37.5%
40.6%
40.6% A
20Net Interest Income (expense)
(8)
(7.2)
(25.1)
(28.2)
(30.2)
(56.9)
(57.3)
100.7
422.9
656.2
673
-
21Net Debt / EBITDA
(0.3)
-
-
(0.3)
(0.3)
0.1
-
(0.1)
-
-
(0.1)
(0.1) A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
809.1
535.2
812.7
1,468
1,618
2,194
2,886
3,106
2,730
2,488
3,118
14.4%
23Short-term investments
236.1
503.5
596.8
1,342
1,597
1,393
2,809
4,636
8,115
6,524
5,487
37%
24Accounts receivable
1,468
1,612
1,974
2,243
2,786
4,115
6,037
5,329
5,667
6,212
5,741
14.6%
25Other current assets
163.5
130.5
225.1
243.3
273.7
160.8
332.4
411.2
386.6
349.2
474.8
11.3%
26Inventory
238.6
399.4
726.1
1,151
1,416
1,917
1,951
2,402
2,581
3,087
3,201
29.7%
27Total Current Assets
3,384
3,914
5,597
7,959
7,689
9,779
14,015
15,884
19,479
18,661
18,022
18.2%
Non-Current Assets
28Net property, plant & equipment
1,594
2,083
2,359
2,576
2,890
3,222
3,482
3,763
4,146
4,600
5,120
12.4%
29Long-term investments
632.2
864.3
1,487
1,755
3,257
3,136
6,838
6,592
5,397
8,900
10,261
32.1%
30Other non-current assets
467.8
845.6
584.2
956.1
968.9
1,027
1,100
2,976
4,058
5,599
7,156
31.4%
31Total Non-Current Assets
2,694
3,793
4,429
5,287
7,116
7,384
11,420
13,330
13,601
19,099
22,537
23.7%
Total Assets
5,609
6,974
8,764
11,735
14,805
17,163
25,435
29,215
33,080
37,759
40,559
21.9%
LIABILITIES
Current Liabilities
32Accounts payable
141
135
178.2
218.2
418.1
475.5
564
589.2
606.6
789.5
939
20.9%
33Short-term debt
-
129.6
-
-
-
-
719.7
-
-
-
-
40.9%
34Other current liabilities
670.2
977
957.3
1,225
1,679
2,222
2,649
2,552
2,817
3,155
3,429
17.7%
35Total Current Liabilities
811.2
1,242
1,136
1,443
2,097
2,697
3,933
3,141
3,423
3,944
4,368
18.3%
Non-Current Liabilities
36Long-term debt
362.9
351.6
703.5
708.5
713.9
2,696
1,980
2,701
2,703
2,704
2,706
22.3%
37Other non-current liabilities
780.2
931.2
781.2
825.9
905
744.9
753.5
707.8
980.8
1,757
2,228
11.1%
38Total Non-Current Liabilities
1,143
1,283
1,485
1,534
1,619
3,441
2,734
3,409
3,684
4,462
4,933
15.8%
39Total Liabilities
1,954
2,524
2,620
2,977
3,716
6,138
6,666
6,551
7,107
8,406
9,302
16.9%
SHAREHOLDERS` EQUITY
40Common stock
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
(0.8)%
41Retained earnings / (deficit)
852.7
1,748
2,947
5,254
7,380
10,893
18,968
23,307
27,260
31,673
35,797
45.3%
42Accumulated other comprehensive income / (loss)
8.6
(12.8)
0.6
(12.3)
21.1
29.3
(26.2)
(238.8)
(80.9)
(7.9)
77.5
24.6%
43Noncontrolling interests
-
-
-
-
-
-
-
-
-
-
-
-
44Total shareholders' equity
3,655
4,449
6,144
8,757
11,090
11,025
18,769
22,664
25,973
29,354
31,257
23.9%
45Total Liabilities and shareholders' Equity
5,609
6,974
8,764
11,735
14,805
17,163
25,435
29,215
33,080
37,759
40,559
21.9%
46Total Debt
375.5
481.1
703.5
708.5
713.9
2,696
2,700
2,701
2,703
2,704
2,706
21.8%
47Net Debt
(433.6)
(54.1)
(109.3)
(759.2)
(903.9)
502
(185.9)
(404.5)
(27.1)
216.2
(412.2)
(0.5)%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
636.1
895.5
1,199
2,444
2,116
3,513
8,075
4,338
3,954
4,413
4,505
21.6%
49Depreciation & amortization
74.9
104.7
145.5
148.2
210.3
235.9
286.2
341.4
421
482.9
543.7
21.9%
50Share-based compensation expense
459
559.9
507.3
427.4
464.3
432
601.7
725
885
982.8
993.7
8%
51Changes in working capital and other assets
160.8
(74.2)
(544.2)
(824.9)
(360.4)
(1,563)
(1,882)
(389.9)
(665.6)
(1,458)
(1,063)
-
52Net cash flows from operating activities
1,331
1,486
1,307
2,195
2,430
2,618
7,081
5,015
4,594
4,421
4,979
14.1%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(677.9)
(511.9)
(272.6)
(383.1)
(429.6)
(614.6)
(551.9)
(590.1)
(926.4)
(755.9)
(1,214)
6%
54Purchases of investments / marketable securities
(557.1)
(809.4)
(1,277)
(1,846)
(3,202)
(3,241)
(7,048)
(7,488)
(11,646)
(16,617)
(10,958)
34.7%
55Proceeds from maturities of marketable securities
327.4
274.5
544.6
775.6
1,604
3,785
2,215
5,551
9,442
15,027
11,546
42.8%
56Other investing activities
-
-
-
(10)
-
-
-
(1,257)
(54.9)
(122.1)
(3.3)
62.8%
57Net cash flows from investing activities
(907.6)
(1,047)
(1,005)
(1,463)
(2,028)
(70.6)
(5,385)
(3,785)
(3,185)
(2,468)
(629.1)
(3.6)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
45.8
(16.5)
(61.5)
(77.1)
(252.1)
(3,952)
(1,006)
(1,009)
(1,090)
(2,167)
(3,335)
-
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
(370.3)
-
60Debt issuance (repayments), net
(140.4)
(40.6)
37.1
-
-
1,982
-
-
-
-
-
-
61Other financing activities
(168.2)
(643.3)
-
-
-
-
-
-
(700.6)
(33.4)
(10.3)
(24.4)%
62Net cash flows from financing activities
(262.8)
(700.4)
(24.4)
(77.1)
(252.1)
(1,971)
(1,006)
(1,009)
(1,790)
(2,201)
(3,715)
30.3%
63Increase (decrease) in cash and cash equivalents
160.4
(273.9)
277.5
655
150.1
577
690.8
221.3
(381.6)
(248.8)
634.7
14.8%
64Cash and equivalents, ending balance
809.1
535.2
812.7
1,480
1,630
2,207
2,898
3,119
2,738
2,489
3,124
14.5%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
652.8
974
1,035
1,812
2,000
2,004
6,529
4,425
3,668
3,665
3,765
19.2%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Regeneron Pharmaceuticals (REGN) financial statements and performance

Explore Regeneron Pharmaceuticals (REGN) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.